Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > SundayMovies Member Since: December 01, 2022

<< Previous

Bullboard Posts

Next >>

Comment by SundayMovieson Dec 07, 2022 11:14am

129 Views

Post# 35156299

RE:RE:SundayMovies Member Since: December 01, 2022

Unnoteworthy,

I think you are not very knowledgeable and often wrong.
Also, your writing is cryptic, confusing and demonstrate maybe a low mental biomarkers level.
Maybe the AWARE trial will help you. Maybe not. I think it will be the latter.

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland